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Abstract: Metabolomics/lipidomics are important tools to identify novel biomarkers associated with
liver damage. Patients with chronic liver disease (CLD) and hepatitis C virus (HCV) infection often
have alterations in glucose, lipid and protein metabolism. The aim of this study was to evaluate if
dysfunctional lipid and amino acid metabolism was associated with fibrosis severity and insulin
resistance in CLD/HCV patients. We analyzed the baseline sera of 75 subjects with CLD/HCV
infection HCV genotype-1, with proven liver biopsy prior to antiviral treatment. We measured
amino acid (AA) and lipid concentration by gas and liquid chromatography-mass spectrometry
respectively. Alterations in peripheral glucose metabolism due to insulin resistance (IR) were assesed
by HOMA-IR (Glucose x Insulin/22.5), while adipose tissue IR was estimated as (Adipo-IR = Free
Fatty Acids x Insulin). Baseline HOMA-IR and Adipo-IR were related to the degree of liver fibrosis.
Reduction in ceramides 18:1/22:0, 18:1/24:0, diacylglycerol 42:6 and increased phosphocholine 40:6
were associated with higher fibrosis. Adipo-IR was related to lower levels of lysophosphatidylcholine
14:0 and 18:2 and with higher levels of sphingomyelin 18:2/24:0 and 18:2/24:1. Almost all AA were
positively associated with Adipo-IR but not with HOMA-IR. We further confirmed the potential use
of metabolomics and lipidomics in CLD/HCV subjects finding novel biomarkers of hepatic fibrosis
and show that the adipose tissue IR is associated with more severe liver disease and is an important
marker not only of altered lipid but also AA metabolism.
Keywords: lipidomics; metabolomics; insulin resistance; fibrosis; amino acids
1. Introduction
Metabolomics and lipidomics are used to assess the metabolic factors involved in the onset of
metabolic diseases, to understand the different metabolic pathways involved in organ damage [1,2].
Several studies have shown that in patients with chronic liver disease (CLD) and HCV infection, insulin
resistance when present affects the liver, muscle and adipose tissue by altering both glucose and lipid
homeostasis [3,4]. Chronic hepatitis C (CHC) infection leads to hepatic inflammation, which stimulates
liver fibrosis [5]. Moreover, HCV infection might be able to disrupt glucose and lipid metabolism via
up-regulation of TNF-alfa and/or down-regulation of suppressors of cytokine signaling and protein
phosphatase 2A [6] that could be implicated in hepatic and extra-hepatic IR [4]. These metabolic
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derangements had been associated with the progression of liver fibrosis and significantly contributed
to a decrease in sustained virological response rate [7] and might persist after completion of treatment.
Liver fibrosis is due to excessive accumulation of extracellular matrix proteins, including
collagen [8], in response to tissue damage caused by HCV infection. Although recent advancements in
direct-acting antiviral (DAA) treatment are able to eliminate viremia, very few treatment strategies can
effective prevent the advancement of liver fibrosis in these patients [5]. Several lipid species, including
mono- (MAGs), di- (DAGs) and tri-acylglycerol (TAGs), ceramides (CER) and lysophosphatidylcholines
(LPC) are implicated in chronic inflammation with consequent effects on multiple organs [9].
In particular the high content of long chain saturated fatty acids (SFA), both in serum and organs, is
associated with lipotoxicity and a worse outcome. Lipotoxicity is the result of increased peripheral
lipolysis due to adipose tissue IR with overflow of free fatty acids to the liver that are in part stored
as triglycerides (steatosis) or converted to lipotoxic species like ceramides [10], although impaired
suppression of lipolysis by insulin have been shown by some [11], but not others [4] in patients
with HCV. Previous studies in patients with NAFLD have associated increased adipose tissue IR to
more severe liver fibrosis [12–14], and recently, Lim et al. have confirmed these data in patients with
CHC [11].
Not only lipid, but also amino acid (AA) metabolism is altered in patients with chronic liver
disease. The serum levels of branched-chain amino acids (BCAA, i.e., valine, leucine and isoleucine)
are usually decreased in patients with liver cirrhosis, while aromatic amino acids (AAAs), such as
tyrosine and phenylalanine, are increased [15]. We have recently shown that AA concentrations, in
particular BCAA, glutamate, serine and glycine, vary with the degree of liver fibrosis in NAFLD [16].
Furthermore, a novel index derived from the AA implicated in the synthesis of glutathione (glutamate,
serine and glycine) and ceramides (i.e., serine), which we called GSG index, was higher in subjects with
severe fibrosis (F3-F4) compared to those with mild/moderate fibrosis and increased proportionally to
IR in both liver and adipose tissue [16].
Considering these previous results, the aim of our study was to evaluate in CLD/HCV patients
if dysfunctional lipid and amino acid metabolism was associated with fibrosis severity and insulin
resistance by measuring alterations in metabolomic/lipidomic profile.
2. Results
The clinical characteristics of the patients divided for fibrosis stage are shown in Table 1.
Subjects with more severe fibrosis were slightly older but, except for GGT (higher in subjects with
severe fibrosis, i.e., F5–F6, p = 0.02), all clinical variables were similar.
2.1. Markers of Insulin Resistance and Inflammation in CLD
Initially, we focused our attention on the associations between degree of liver fibrosis (as an index
of severity of CLD) and IR indexes, i.e., HOMA, which reflects impaired insulin action in glucose
metabolism, and Adipo-IR, which reflects the impairment of the antilipolytic effect of insulin resulting
in higher circulating free fatty acids. Subjects were grouped according to the severity of liver fibrosis
as: low (F1–F2), mild (F3–F4) or severe (F5–F6) fibrosis. We found that not only HOMA-IR, but also
Adipo-IR was significantly increased with the worsening of fibrosis (Table 1). The leptin and MCP-1
serum concentration were similar among patients with different stages of fibrosis or IR (Table 1),
although leptin was associated with SVR.
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Table 1. Clinical characteristics of Chronic Liver disease/HCV patients according with fibrosis stage.
Variable F1–F2 F3–F4 F5–F6 p Value
Gender (M/F) 15/14 11/15 6/6 ns
Age (y) 45.5 ± 2.14 48.3 ± 2.3 52.5 ± 3.1 0.026
BMI 23.2 ± 0.6 23.8 ± 0.6 24.7 ± 1.3 ns
Cholesterol (mg/dL) 169.2 ± 7 169.3 ± 8.4 161.1 ± 7.7 ns
LDL (mg/dL) 102.5 ± 4.9 101.4 ± 6.6 97.5 ± 6.8 ns
HDL (mg/dL) 41.9 ± 2.6 38.7 ± 3.7 39.5 ± 4.3 ns
Triglycerides(mg/dL) 123.7 ± 9.9 146.2 ± 17.5 120.6 ± 13 ns
AST (mU/L) 8.0 ± 0.9 6.2 ± 0.7 8.9 ± 1.3 ns
ALT (mU/L) 9.3 ± 1.1 7.7 ± 0.9 8.2 ± 1.13 ns
GGT (mU/L) 38 ± 3.6 31 ± 4.4 58.6 ± 10.5 0.021
Glucose (mg/dL) 67.8 ± 2.3 68.2 ± 3.2 76.4 ± 5.2 ns
Insulin ulU/mL 11.9 ± 0.9 12.8 ± 1.3 16.1 ± 1.8 ns
MCP-1 pg/mL 223.9 ± 16 218.8 ± 26. 188.4 ± 22.2 ns
Leptin pg/mL 3000 ± 632 3149 ± 547 65,340 ± 2345 ns
HOMA-IR 36.6 ± 1.2 38.7 ± 3.8 54.6 ± 6.3 0.024
Adipo-IR 10.7 ± 1.2 18.1 ± 2.4 18.8 ± 3.2 0.042
Gender (M/F) 15/14 11/15 6/6 ns
Age (y) 45.5 ± 2.14 48.3 ± 2.3 52.5 ± 3.1 0.026
BMI 23.2 ± 0.6 23.8 ± 0.6 24.7 ± 1.3 ns
Cholesterol (mg/dL) 169.2 ± 7 169.3 ± 8.4 161.1 ± 7.7 ns
LDL (mg/dL) 102.5 ± 4.9 101.4 ± 6.6 97.5 ± 6.8 ns
HDL (mg/dL) 41.9 ± 2.6 38.7 ± 3.7 39.5 ± 4.3 ns
Triglycerides(mg/dL) 123.7 ± 9.9 146.2 ± 17.5 120.6 ± 13 ns
AST (mU/L) 8.0 ± 0.9 6.2 ± 0.7 8.9 ± 1.3 ns
ALT (mU/L) 9.3 ± 1.1 7.7 ± 0.9 8.2 ± 1.13 ns
GGT (mU/L) 38 ± 3.6 31 ± 4.4 58.6 ± 10.5 0.021
Glucose (mg/dL) 67.8 ± 2.3 68.2 ± 3.2 76.4 ± 5.2 ns
Insulin ulU/mL 11.9 ± 0.9 12.8 ± 1.3 16.1 ± 1.8 ns
MCP-1 pg/mL 223.9 ± 16 218.8 ± 26. 188.4 ± 22.2 ns
Leptin pg/mL 3000 ± 632 3149 ± 547 65,340 ± 2345 ns
HOMA-IR 36.6 ± 1.2 38.7 ± 3.8 54.6 ± 6.3 0.024
Adipo-IR 10.7 ± 1.2 18.1 ± 2.4 18.8 ± 3.2 0.042
BMI = Body Mass Index; LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein; AST = Aspartate
Aminotransferase; ALT = Alanine aminotransferase; GGT = Gamma-Glutamyl-Transpeptidases; MCP-1 = Monocyte
chemotactic protein-1; HOMA-IR = homeostatic model assessment; Adipo-IR = Adipose Tissue IR.
2.2. Lipidomic Profile in Relation to Fibrosis Stage and Insulin Resistance
We performed targeted lipidomics of sera by ultra-high performance liquid
chromatography-quadrupole time-of-flight mass spectrometry (UHPLC/QTOF-MS). The lipid
composition and concentrations of the following species were measured: ceramides (CER),
phosphocholines and lyso-phosphocholines (PC, LysoPC) for which we report both quantitative
and qualitative analyses, mono-, di- and tri-acylglycerols (MAGs, DAGs, TAGs) and sphingomyelin
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(SM), which were evaluated only in qualitative mode. Lipidomic profiles were globally compared
by using Partial Least Square Discriminant Analysis (PLDA), a supervised classification method
which optimizes the separation among the different groups of samples (Figure 1A). PLDA shows that
subjects with severe fibrosis (F5–F6) are separated by the other two groups. Heat maps reveal that
several species of lipids were related to the increase of fibrosis stage (Figure 1B). However, seven
metabolites were differentially abundant among the three groups (Figure 2A). Specifically, PC 40:6 was
higher in subjects with fibrosis grade F5–F6 versus F1–F2 (p = 0.004), while ceramides CER(18:1/24:1),
CER(18:1/22:0), CER(18:1/24:0) and CER(18:1/16:0) generally showed lower concentrations in F5–F6
respect to F1–F2 or F3–F4 (Kruskal-Wallis p < 0.05, see Figure 2A for details). Moreover, concentrations
of DAG 42:6 e in general DAG with more than five double bounds (DAG 5–6, i.e., containing mainly
unsaturated fatty acids) were different among the three groups. Using binomial logistic regression
analysis to discriminate between extreme groups (low versus severe fibrosis) showed that ceramides
CER(18:1/24:1) and CER(18:1/22:0) (as single variables or in combination) are the best ceramides
species able to discriminate the severity of fibrosis as measured by ROC-AUC (Area Under the ROC)
(Figure 2B). Moreover, several lipids were associated with IR either in the adipose tissue or muscle
(Figure 3).
2.3. Association between Amino Acid Profile, Fibrosis Stage and Insulin Resistance
AA concentrations were measured in serum of all patients by GC/MS and related to IR and fibrosis
stage. Almost all AA were positively associated with the presence of IR, in particular with Adipo-IR
but not with HOMA-IR (Figure 3).
Only the combination of BCAA and AAAs were increased with fibrosis (p = 0.023; Figure 4B),
while the BCAA/AAA ratio was not related to fibrosis stage. The GSG index (i.e., the ratio of
glutamate/(serine and glycine)), that combines AA involved in glutathione and ceramides synthesis,
was significantly associated with increased liver enzymes (GGT, R= 0.37 p = 0.0027 and AST, R = 0.46
p = 0.022) confirming our previous report showing the association of GSG index with liver damage [16].
GSG index tended to be higher in patients with fibrosis stage ≥ 5 (Figure 4C) and was associated with
viral load.
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Analysis (PLS- ). (B) Heat maps of plasma lipid according to low (F1–F2) and severe (F5–F6)
fibrosis level.
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2.4. Baseline Markers of Response to Therapy (SVR)
Our condary aim wa t evaluat if any of the lipids or amino acids measured pre-treatment
could identify patients with a better sustained virological response to treatment. The 75 patients were
divided in two groups, i.e., “responders” when a sustained virological response (SVR) was obtained
(n = 36 patients, coded as “R”) versus “non responders” (n = 39 patients, coded as “NR”)
First, we observed that pre-treatment degree of IR was associated with SVR as both HOMA-IR
and Adipo-IR were higher at baseline in “NR” subjects compared to “R” (HOMA-IR 48.4 ± 4.3 versus
36.8 ± 3.1; Adipo-IR 16.9 ± 2 versus 12.3 ± 1.2).
Second, lipidomic analysis showed that “R” patients showed increased concentrations of LysoPC,
in particular saturated LysoPC like LPC 16:0 and 18:0 (p < 0.05) and ceramides (p = 0.0006), in particular
of CER(18:1/14:0), CER(18:1/16:0), CER(18:1/22:0) and CER(18:1/24:0). Among sphingomyelin (SM),
only SM 16:1/24:0 was higher in “R” compare to “NR” while no difference was observed in PC profile.
The analysis of TAGs and DAGs profile showed similar serum concentrations total TAGs and DAGS
although patients “NR” have more saturated TAGs compared to “R” patients (p < 0.05), while no
difference was observed in DAGs between the two groups (Figure 5)
The amino acid profile was different between “R” and “NR” patients. “NR” patients had higher
serum concentrations of glutamate and proline than patients responding to PEG-IFN therapy, while
the concentrations of other amino acids, including AAA and BCAA were similar in the two groups
(Table 2). Several AA were related to viral load such as glutamate, isoleucine, lysine, proline, tyrosine
BCAA and AAA. We founded that GSG index was associated with viral load and “NR” patients had
significantly higher GSG index before treatment compared to “R” patients (Figure 6).
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Table 2. Amino acids profile and its relationship with SVR and viral load.
Amino Acids
mmol/L Non Responders Responders NR vs R (p Value) Viral Load (R)
Alanine 517.38 ± 25.4 508.10 ± 29.88 ns ns
Phenylalanine 132.73 ± 7.65 129.78 ± 9.6 ns
Glycine 287.4 ± 12.6 289.13 ± 15.62 ns
Glutamate 455.5 ± 29.08 346.12 ± 33.52 0.006 R = 0.38
Histidine 131.75 ± 16.57 133.92 ± 8.12 ns
Leucine 348.1 ± 34.73 323.98 ± 40.71 ns
Isoleucine 83.68 ± 3.82 78.53 ± 5.41 ns R = 0.25
Lysine 282.2 ± 22.08 262.76 ± 31.81 ns R = 0.23
Proline 275.13 ± 21.44 213.46 ± 20.74 0.04 R = 0.34
Serine 259.5 ± 15.53 247.81 ± 20.47 ns
Tyrosine 137 ± 8.58 120.27 ± 11.14 ns R = 0.27
Valine 174.81 ± 8.9 169. ± 10.7 ns
BCAAs 528.92 ± 31.25 496.7 ± 31.1 ns R = 0.32
AAAs 258.26 ± 13.92 258.33 ± 21.17 ns R = 0.32
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The adipose tissue is also an endocrine organ that secretes hormone such as leptin, which plays 
an important role in the regulation of body fat and in the development of hepatic fibrosis [23]. In our 
cohort of patients, leptin was higher in “NR” patients before treatment, although it was not 
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Figure 6. Basal GSG index was higher in NR patients (A) and positively associated with viral load (B).
* p value= 0.05.
3. Discussion
Several studies have used lipidomic and metabolomic analyses of serum samples to identify early
biomarkers of liver disease in NAFLD/NASH, while nly a few have used these novel tools to identify
biomarkers of liver damage (particularly fibrosis stage) a d response to treatment i patients with
chronic l ver dis a e of a different etiology. In patient with l ver disease of varying tiology nd severity,
insulin resistance and amino acid metabolism are altered, in particular AAA, which is met bolized
mainly by th liver [17]. Mo over, HCV infection is associ ted with alterations i glucose, lipid and
amino acid metabolism, lipid synthesis and clearance and insulin resistance [4,18]. Hepatitis C virus
cons st of rep icates principally in hepatocyt s; other organs are also affected by the virus, such as
muscle, adipose tissue and pancreas [11,19,20], leading to comorbidities such as type 2 diabetes, renal
and cardiovascular disea e and fibrosis in iver [5].
We mea red the lipidomic and met bolomic pr files and their association w th insulin resistance
in relation to liver fibros s and virological response to treatment in patients with chronic liver disease
and HCV inf ction. Insulin resistance to gluc se and lipid metab lism is a pro-fibroge etic s imulus [21].
Previously, researchers has show that patients with HCV have impaire glucose metabolism due to
increased IR n both muscle and li er, and thi was as ociated with more sev re liver fibrosis [3,4,22].
IR may be present als n a ipose tissue due to the resistanc to the antilipolytic effect of insulin
resulting in increased lipolysis that in turn promotes liver lipotoxicity, as a consequence of FFA
overflow to the liv r [10]. In this study, our patients showed IR both in liver/muscle and at the level
of ad pose tissue, and this was associated ith the wo sening of fibrosis, in agreement with recent
data by Lim et a . [11]. In subjects with NAFLD adipose tis ue, IR i associated with the verity of
hepatic fibrosis [12–14]. However, while most of patients with NAFLD have excess fat accum lation,
most of the CLD patients are lean; thus, increa ed Adipo-IR might expla n the low subcutaneous fat
accumul tion due to accelerated lipolysis.
The dipose tissue is also an endocrine organ that secretes hormone such as leptin, which plays
an important role in the regulatio of body fat and in the develop e t of hepatic fibrosis [23]. In our
cohort of patients, leptin was higher in “NR” patie ts before treatment, although it was not associated
with IR, fibrosis taging or steatosis, similar to the results o tained by Grasso et al. [24]. High baseline
erum leptin levels might represent a n gative prognos ic factor for response to antiviral therapy that
should be further investigated.
We studied if and how the lipidomic profile was associated with fibrosis stage (i.e., low (F1–F2),
mild (F3–F4) or severe (F5–F6)). We f und that s ven erum lipid species resulted differentially abundant
among the th ee groups. Particularly PC 40:6 was higher in F5–6 versus F1–2, while ceramides CER
(18:1/24:1), CER (18:1/22:0), CER (18:1/24:0) and CER (18 1/16:0) showed lower le els in F5–6 respect to
F1–2 or F3–4. Moreover, DAG with more than five double bounds DAG 5–6) and DAG (42:6) were
found differen among the three groups of subjects. The logistic regr ssi n analysis u ed to discrimi ate
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between extreme fibrosis groups (i.e., low versus severe) showed that ceramides CER (18:1/24:1) and
CER (18:1/22:0) (as single variables or in combination) were the best in discriminate severity of fibrosis
(Figure 2B). Ceramides have been identified as potent regulators of signaling in several biological
pathways and affect hepatocellular susceptibility to various stimuli [25] including the regulation
of HCV replication [26]. Ceramide molecules are composed of a sphingosine backbone bound to
fatty acids with different chain lengths. Recent studies have revealed that long-chain (C16–C20) and
very-long-chain (C22–C24) ceramides express opposite effects on cell proliferation, i.e., very long
chain CER promote proliferation in vitro contrary to the pro-apoptotic effects of long chain CER, in
various cell types [27–29]. In our study, the serum concentration of two very long chain ceramides
(CER (18:1/24:1) and CER (18:1/22:0)) was lower in severe fibrosis. Moreover, patients with severe liver
fibrosis had higher levels of PC 40:6.
We also observed differences in phospholipids abundances, particularly between responder and
non-responder, and several phospholipids were associated with IR as shown by the matrix correlation
in Figure 3. This result agrees with previous data that reported that phospholipids play a critical role
in physiological processes and in modulation of insulin sensitivity [30].
Not only lipid, but also amino acid metabolism is frequently altered in patients with liver
diseases [31]. An imbalance in the levels of AAAs or BCAAs is commonly seen in patients with
chronic liver disease [17] and most changes in serum AA concentrations in patients with CLD could
be due to the impairment in hepatic function, hyperinsulinemia and hyperglucagonemia [32]. In the
present study, our results showed that only BCAA and AAAs were associated with severity of fibrosis.
Particularly the amino acid profile has highlighted that almost all AA were associated with the increase
of adipose IR and not with muscle IR. Our previous data in non-obese NAFLD have shown that
alteration in AA metabolism is independent of degree of obesity, but associated with IR. We have found
higher serum levels of isoleucine and valine (BCAAs), tyrosine (AAA), alanine, lysine and glutamate in
subjects with fatty liver disease while the plasma concentration of glycine was significantly lower; the
GSG index, (glutamate/serine + glycine) was related to an increased level of liver enzymes, particularly
gamma-glutamyltransferase, and liver fibrosis in non-obese and obese NAFLD [16]. In this group of
patients we also found that GSG index was significantly associated with liver enzymes and tended to
be higher in patients with severe fibrosis. The increase in GSG index reflects an alteration in hepatic
function and/or related to an increased demand in glutathione (GSH) and its transamination by GGT,
confirming our previous report that showed the association between GSG index and liver damage in
patients with NASH [16].
The secondary aim of this study was to identify which metabolite/lipid was associated with viral
load and SVR. Several amino acids were related to baseline viral load i.e., glycine, isoleucine, lysine,
proline tyrosine and AAAs. Patients who got SVR had significant lower baseline serum concentrations
of glutamate and proline and the GSG index. Lipidomic analysis showed that several classes of lipid
were higher in serum of patients “NR” before treatment. We observed that ceramides CER (18:1/14:0),
CER (18:1/22:0), CER (18:1/24:0) and Lyso-PCs LPC-18:0 and LPC-16:0 were different in (R) patients
compare (NR). We also found that degree of fatty acid unsaturation, evaluated by number of double
bonds in TAGs and DAGs, was higher in patients “NR” (Figure 5). This negative metabolic profile in
“NR” patients indicates the importance of lipid glucose metabolism in all CLD.
This study has some limitations. First it is a cross-sectional study, making it difficult to dissect
the relationship between the new biomarkers discovered and their interplay with the metabolic
complications and liver disease/severity. Although the relationship between baseline metabolic
alterations and response to treatment were significant, the treatment here used as an example of SVR is
no longer used. Thus, these findings should be investigated after the current most common treatment,
DAAs, to confirm if metabolic factors are crucial for successful response to treatment. Moreover, a
group of subjects with liver disease (i.e., a control group) would be useful to better understand the
metabolic differences in patients with different chronic liver diseases.
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In conclusion, this study confirmed that Adipo-IR is associated with more severe liver disease
also in patients with CLD/HCV and is an important marker not only of altered lipid but also AA
metabolism. Moreover, the GSG index was associated to high viral load before treatment. These results
further confirmed the use of metabolomics and lipidomics for the identification of subjects with most
severe liver disease.
4. Materials and Methods
We performed metabolomic/lipidomic analyses on the sera of 75 patients positive for HCV (all with
Genotype-1) previously enrolled in the Gastro-Hepatology Division of the University Hospital Torino,
Italy for a multicenter project (described in reference [33]). Inclusion criteria were: (1) diagnosis of
chronic hepatitis C with G1 infection based on hepatitis C serology and viral RNA, (2) histologic
diagnosis on liver biopsy, and (3) alcohol consumption less than 20 g/d in the past 12 months.
All participants were recruited after providing written informed consent. Some clinical and biochemical
characteristics of the study cohort has been previously published [33]. Patients were excluded from
the study if they were co-infected with either the hepatitis B virus or human immunodeficiency virus,
if they were affected from diabetes or if they were not of northern European descent. All patients
were tested at the time of biopsy for HCV RNA (limit of detection 12 IU/mL). HCV RNA levels were
quantified at baseline and viral load was classified as low (≤850,000 IU/mL) or high (≥850,000 IU/mL).
Primary aim of this study was to evaluate which metabolites (AA or lipids) were altered in
patients with CLD and severe fibrosis. Liver fibrosis was staged in the biopsy according to an Ishak
score [34]. For this analysis, patients were divided in three groups according to the severity of liver
fibrosis, according to the Ishak score [34]: as low (F1–F2), mild (F3–F4) or severe (F5–F6) fibrosis.
Low fibrosis F1–F2: fibrous expansion of some portal areas, with or without short fibrous septa (score
1), fibrous expansion of most portal areas, with or without short fibrous septa (score 2). Mild fibrosis
F2–F3: fibrous expansion of most portal areas with occasional portal to portal (P-P) bridging (score 3),
fibrous expansion of portal areas with marked bridging portal to portal (P-P) as well as portal to central
(P–C)) (score 4). Fibrosis severe F5–F6: marked bridging (P-P and/or P-C) with occasional nodules
(incomplete cirrhosis) (score 5), cirrhosis, probable or definite (score 6). The metabolomic/lipidomic
analyses were performed by mass spectrometry (see below). In addition, we measured markers of
adipose tissue dysfunction, as serum concentration of leptin and monocyte chemoattractant protein-1
(MCP-1), a marker of microphage inflammation by Luminex technology (Merckgroup, Darmstadt,
Germany), and free fatty acid (FFA) concentrations, (Fujifilm WAKO Diagnostic, USA). Liver enzymes
were measured by chemistry analyzer Beckman Coulter Olympus AU400 (Ireland).
A secondary aim was to evaluate which metabolite/lipid was associated with sustained virological
response (SVR). In this group, 36 patients responded to the antiviral therapy (R), based on SVR after
treatment with PEG-IFNa plus RBV, while 39 patients were considered as non-responders (NR).
4.1. Lipidomic and Metabolomic Measurements
Lipidomic analysis was performed using a High Performance Liquid Chromatography (Agilent
UHPLC 1290) coupled with a Quadrupole Time-Of-Flight Mass Spectrometry QTOF (QTOF-MS,
Agilent 6540) equipped with electrospray ionization source (ESI). Fasting serum samples (10 uL)
were first deproteinized using cold methanol (200 uL). For liquid chromatography analysis, we
used an Agilent ZORBAX Eclipse Plus C18 2.1 × 100 mm 1.8-Micron column at 50 ◦C. The mobile
phase A was water with 0.1% formic acid and the mobile phase B was isopropanol/acetonitrile
(1:1, v:v) with 0.1% formic acid. Injection volume was 1 uL. We performed untarget acquisition
of sample spectra. Quantitative analysis was performed with internal standards added to the
sample before deproteinization, i.e., Ceramide (CER (d18:1/17:0)), Phosphocholine (PC(17:0/17:0))
and Lysophosphatidylcholine (LPC(17:0)) (Avanti Polar Lipids, Sigma Aldrich, St Louis, MO, USA).
For MAGs, DAGs, TAGs and sphingomyelin (SM), we performed a qualitative analysis and evaluated
the proportion of unsaturated to saturated fat (i.e., double bonds).
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Metabolomic analysis (polar metabolites) was performed by Gas Chromatography (GC)-Mass
Spectrometry (MS) (Agilent technology GC-7890/MS-5975; Santa Clara, CA, USA), equipped with a
DB-5 column (J&W, Agilent, Santa Clara CA, USA). Briefly, 80 uL of serum sample were deproteinized
with 1 mL of cold methanol after adding a mix of 13C labeled internal standards of amino acids
(Celtone, CIL Cambridge, MA, USA) that contains uniformly labeled phenylalanine, tyrosine, leucine,
isoleucine, valine; alanine, lysine, hystidine, proline, threonine, glutamate, serine and glycine.
After deproteinization, samples were purified through a cationic resin (BIORAD), dried under
nitrogen, derivatized using N-methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide (MSTBSTFA,
Sigma, USA) and injected in the GCMS equipped with an Agilent J&W HP-5ms column. The spectra
were acquired in SIM/SCAN mode.
4.2. Calculation and Statistical Analysis
We calculated indexes of insulin resistance as HOMA-IR index (fasting glucose × fasting
insulin/22.5) that reflects fasting insulin resistance relative to glucose metabolism in muscle/liver [35]
and adipose tissue IR (Adipo-IR) index evaluated as the product (FFA × insulin) [36], which measure
the resistance to the antilipolytic effect of insulin.
From amino acids profile, we calculated Equations (1)–(3); Equations (1) includes AA involved in
the synthesis of glutathione (glutamic acid and glycine) and of ceramides (serine) [16]:
GSG index = glutamic acid/(serine + glycine) (1)
BCAAs = (leucine + valine + isoleucine) (2)
AAAs = (tyrosine + phenylalanine) (3)
BCAA/AAA, which is reduced with severity of liver disease, mainly because the concentrations of
AAA that are metabolized mainly in liver tend to be increased with severity of liver disease as a sign of
the impairment in hepatic metabolism [17].
For DAG and TAG, we calculated the number of double bonds, i.e., the degree of unsaturation.
Metabolomic and lipidomic data were jointly analyzed using MetaboAnalystR 1.0.3 software
(XiaLab at McGill University, Montreal, Quebec, Canada) [37]. After log transformation and auto scaling
(e.g., mean-centered and divided by standard deviation of each variable), Principal Component Analysis
(PCA), Partial Least Squares-Discriminant Analysis (PLS-DA) and heat maps were performed using
MetaboAnalystR 1.0.3. We performed quality control of samples using PCA that allowed us to label the
68 samples as outliers, which were then excluded from downstream analysis. Nonparametric statistical
methods, including Mann−Whitney U test, Kruskal−Wallis and Spearman rank correlation analysis,
were performed using “R: A Language and Environment for Statistical Computing” (R Foundation for
Statistical Computing, 2008 Vienna, Austria) or SPSS 13.0 (SPSS Inc, Chicago, IL, USA) as data were
not normally distributed. Regression analysis and Receiver operating characteristic (ROC) curves
for modulated single or combined metabolites were performed using the R software as a binary
classification model for discriminating low from high level fibrosis and evaluated by the area under the
curve (AUC) and 95% confidence interval, as well as p-value. Data are presented as the mean ± SEM.
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Abbreviations
CLD Chronic Liver Disease
IR Insulin Resistance
DAA Directly Acting Antivirals-
SVR Sustained Virological Response
PEG-IFNa Pegylated-Interferon-A
RBV Ribavirin
GC/MS Gas Chromatography Mass Spectrometry
UHPLC/MS-QTOF
Ultra-High Performance Liquid Chromatography-Quadrupole
Time-Of-Flight Mass Spectrometry
HOMA Homeostasis Model Assessment
BCAA Branched-Chain Amino Acids
AAA Aromatic Amino Acids
SFA Saturated Fatty Acids
Cer Ceramides
PC Phosphocholines
LysoPC Lysophosphtidilcholines
MAG Monoacylglycerols
DAG Diacylglycerols
TAG Triacylglycerols
SM Sphingomyelin
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